SABCS 2024: Disitamab Vedotin Demonstrates Clinically Meaningful Results in the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis

A RemeGen-sponsored, randomized, open-label, multicenter phase 3 study comparing the efficacy and safety of disitamab vedotin versus treatment with the tyrosine kinase inhibitor lapatinib + capecitabine in patients with HER2-positive advanced breast cancer with liver metastasis.

Authors

Publication Details

Journal
ADC Review / Journal of Antibody-drug Conjugates
Published
2024-12-13
DOI
https://doi.org/10.14229/jadc.2024.12.13.001
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SABCS 2024: Disitamab Vedotin Demonstrates Clinically Meaningful Results in the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis

Peter Hofland
ADC Review / Journal of Antibody-drug Conjugates
HER2/EGFR in Cancer Research
article

SABCS 2024: Disitamab Vedotin Demonstrates Clinically Meaningful Results in the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis

Peter Hofland
article en

Abstract

A RemeGen-sponsored, randomized, open-label, multicenter phase 3 study comparing the efficacy and safety of disitamab vedotin versus treatment with the tyrosine kinase inhibitor lapatinib + capecitabine in patients with HER2-positive advanced breast cancer with liver metastasis.

ADC Review / Journal of Antibody-drug Conjugates
Openalex Percentile: Top 58%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

SABCS 2024: Disitamab Vedotin Demonstrates Clinically Meaningful Results in the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis — Peter Hofland · ADC Review / Journal of Antibody-drug Conjugates (2024) | TGRS Research Map | TGRS